NCT00085956

Effects of Arzoxifene on Bone Mass and the Uterus

Effects of Arzoxifene on Bone Mineral Density and Endometrial Histology in Postmenopausal Women.

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 300 (planned)
• Sponsor: Eli Lilly and Company · Industry
• Sex: Female
• Age: 45 Years – 60 Years
• Healthy volunteers: Accepted

Summary

The purposes of this study are to determine: * The effects of arzoxifene on bone mineral density (bone mass) at the spine and hip in postmenopausal women. * The effects of arzoxifene on the uterus (womb) in postmenopausal women. * The effects of arzoxifene on blood tests that measure changes in bone rebuilding in postmenopausal women with low bone density. * The effects of arzoxifene on blood lipids (fats) and other blood markers of heart disease risk. * The safety of arzoxifene and any side effects that might be associated with its use.

Conditions

• Postmenopausal Bone Loss

Interventions

Type	Name	Description
DRUG	Arzoxifene
DRUG	Placebo

Timeline

• Start date: 2004-04-01
• Completion: 2007-02-01
• First posted: 2004-06-22
• Last updated: 2007-03-09

Locations

1 site across 1 country: United States